SEKISUI 化学 CO.有限公司. (总部: Osaka; President and Representative Director: Teiji Koge; hereinafter, “SEKISUI 化学”) concluded a 业务 cooperation agreement with Cyfuse Biomedical K.K. (总部: Bunkyo-ku, 东京, 首席执行官: 静香Akieda; hereinafter, “Cyfuse”), 发展, 生产, and sells regenerative medicine-related products.
1. Background and Aims
SEKISUI 化学’s High Performance Plastics Company (President: Keita Kato) has positioned life sciences as one of its strategic areas, making efforts to expand its medical 业务 carried out centrally by its 100% wholly-owned subsidiary, Sekisui医疗公司.有限公司. (总部: Chuo-ku, 东京, President and Representative Director: Hideo Tagashira; hereinafter, “SEKISUI医疗”). SEKISUI MEDICAL, in the 5-year midterm management strategy “HIYAKU 2020”*1 which covers FY2016 through FY2020, positioned entering into new markets as one of its basic strategies, aiming to expand its drug development solutions 业务 mainly in 欧洲 and America. Using SEKISUI 化学’s consolidated subsidiary SEKISUI XENOTECH, LLC. 作为它的基础, it has been developing the drug development solutions 业务, mainly in 欧洲 and America with the aim of expanding 业务 by improving the capabilities of in-vitro testing*2 services and strengthening ties with SEKISUI MEDICAL’s 日本 base.
The cooperation target company, Cyfuse, has its own three-dimensional cell accumulation technology for manufacturing three-dimensional tissues and organs without utilizing scaffolds*3 in the regenerative medicine field, aiming at the practical application of innovative cell products to osteochondral, 血管, and peripheral nerves etc. 再生.
Cyfuse has also spread its basic technology in the drug development field by developing and selling its cell 3D printer Regenova®. 除了, it has developed three-dimensional hepatic structures with high hepatic function over the long term as testing tools for safety and toxicity evaluation in new drug development.
SEKISUI 化学 has concluded the 业务 cooperation agreement with Cyfuse with the aim of applying the hepatic structures which Cyfuse has developed to the drug development solutions 业务 developed by SEKISUI MEDICAL. 另外, through the cooperation, SEKISUI 化学 plans to deepen knowledge, not only in the drug development solutions 业务, but also in the regenerative medicine area, in order to expand 业务 operations in the life sciences field in the future.
SEKISUI 化学’s High Performance Plastics Company also continues to accelerate cooperation with ventures and academia to expand and strengthen its strategic areas and to promote similar 业务 cooperation to explore new technologies and new 业务es.
|
*1 |
|
|
*2 |
In-vitro testing: Drug reaction testing in an environment outside the body that is equivalent to that inside the body. |
|
*3 |
Scaffold: Material which holds cell structures, accelerating cell proliferation. |
2. Cyfuse概述
|
(1) |
名字 |
Cyfuse Biomedical K.K. |
|
(2) |
总部 |
The University of 东京 Entrepreneur Plaza, 7-3-1 Hongo, Bunkyo-ku, 东京 |
|
(3) |
首席执行官 |
静香Akieda |
|
(4) |
业务 |
Development and manufacturing of regenerative medicine-related products, development of drug development solution tools, and development and sale of devices. |
|
(5) |
建立了 |
2010年8月11日 |
|
(6) |
网站 |
免责声明
This press release may contain forward-looking statements. Such forward-looking statements are based on current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements due to changes in global economic, 业务, competitive market and regulatory factors.